We retain US commerical rights to all of our oncology and inflammation programs
As of IPI-926 presentation at ASCO (click here for details), PFS not yet hit, was at 5.5m. Compare this to historical data which is <3m for gemcitabine alone
IPI-926 myelofibrosis trial initated 10/2011 other agents in development for this indication just reduce spleen size and address symtpoms...do no address the underlying disease
chondrosarcoma - surgery for this condition is incredibly deforming/disfiguring because it is localized in major joints. We are now actively enrolling, seeking about 140 pts 2:1 randomization with crossover at about 50 sites.
IPI-504 re HSP90 ocular toxicity - we did see toxicity. [all other times they have said "we have not seen significant ocular toxicity"...now dropped the word significant]
heavy smokers make up ~2/3 of NSCLC, KRAS mutants make up 30%, squamous cell histology makes up 35%- we have covered these populations in phase 2 trials
IPI-926 pancreatic cancer trial enrollment is complete
ALNY (click for stock research page) presented 10/21 at the BioCentury Newsmakers Conference (find webcast link and complete biotech webcast calendar on Upcoming Events page)
speaker: Chief Business Officer (CBO)
no slide deck online
rapidly growing RNAi human database, >500 patients...gives info on efficacy, mechanism of action, phamcology, safety
TTR02 IND "late this year"
PCS - RNAi can reduce PCSK9 levels inside and outside of cells, which monoclonal antibody approach can't do
Biotherapeutics program - have been "incubating this idea over last 2 years or so." Think we can improve the next generation of novel therapeutics, biobetters, and biosimilars [but doesn't sound like trying to work with partners to change production methods for current drugs]... scales nicely into bioprocessing /manufacturing systems..We plan to develop this business as go into next year as a revenue stream back into parent compnay. 2 large pharma partnerships now
APC program is transitioning from "research" to "development" phase